Skip to main content
Clinical Trials/NCT04105296
NCT04105296
Unknown
Phase 1

Epidural Stimulation for Locomotion After Spinal Cord Injury

McGuire Research Institute1 site in 1 country5 target enrollmentJanuary 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Spinal Cord Injuries
Sponsor
McGuire Research Institute
Enrollment
5
Locations
1
Primary Endpoint
Surface electromyography of 6 different muscle groups
Last Updated
6 years ago

Overview

Brief Summary

The purpose of the current study is to determine the effects of applying epidural stimulation (ES) on motor control recovery in Veterans with SCI. The intervention will be accompanied with the use of a powered exoskeleton (EKSO®) for 6 months to facilitate standing and to produce step-like movement in persons with chronic motor complete (AIS A or B) SCI and level of injury below C5 . Walking speed, distance, muscle activation pattern as measured by surface EMG and walking parameters including stand-up time, walking time, distance will be considered primary outcome variables. Cardiovascular performance, as measured by resting blood pressure and heart rate, peak oxygen consumption during walking, energy expenditure, whole and regional body composition assessments will also be measured. The effects of training (ES+EKSO) on , and speed of walking will also be evaluated.

Detailed Description

Five veterans with chronic motor complete SCI (AIS A or B) will be recruited to participate in the current trial. The primary objective is to determine how implantation of an epidural stimulator can help to control movement in the leg muscles to stand and perform stepping. Participants will be trained using a robotic suit and parallel bars. The procedure of using epidural stimulation with the robotic suit is experimental. The participant will be scheduled to perform temporary implantation followed by permanent implantation. Seven days later, two 8-electrode arrays of Vectris lead will be implanted in an operating room. The research team will be responsible for helping the participants to trigger the paralyzed muscles from supine and sitting using for 5 days per week. Participants would be required to come for study visits twice daily for 2 hours per day. Each visit will last approximately 1 hour in the morning and 1 hour in the evening. During these visits, participants will practice walking with a robotic suit for 30-60 minutes followed by overground walking between parallel bars, or with a walker or crutches.

Registry
clinicaltrials.gov
Start Date
January 2020
End Date
December 30, 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
McGuire Research Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A written clearance by the medical doctor to ensure that the participant is safely able to engage in the program.
  • Participants who require assistance with activities of daily living, must have a caregiver or companion with them throughout their participation in the study.
  • Participants will have to be 2 years post-injury with any level of injury below C5 and using wheelchair as the primary mode of mobility. The study is primarily exploratory, and all participants will be between 18-70 years old with SCI.
  • Hip width (distance between two greater trochanters), upper leg length (greater trochanter to the lateral aspect of joint line of the knee joint) and lower leg length (lateral aspect of joint line of the knee joint to the bottom of the foot) that can fit the robotic suit.

Exclusion Criteria

  • Unhealed fracture in either lower or upper extremities
  • Severe scoliosis, hip knee ROM or flexion knee contractures preventing positioning in an exoskeleton or plantarflexion deformity greater than 20 degrees.
  • High resting blood pressure greater than 140/80 mmHg and or sudden hypotension upon standing as characterized by drop in blood pressure by 20 mmHg especially in persons with tetraplegia.
  • Other medical conditions including cardiovascular disease, uncontrolled type II DM, uncontrolled hypertension, and those on insulin, pressures sores stage 3 or greater, or symptomatic urinary tract infection.
  • Unable to fit in the device for any reason.
  • Taking anti-coagulants or anti-platelet agents, including aspirin if unable to be off this medication for medical reasons.
  • Implanted pacemakers and/or implanted defibrillator devices.
  • Any condition that, in the judgment of the principal investigator or medical provider, precludes safe participation in the study and/or increases the risk of infection.
  • Dual Energy X-ray Absorptiometry (DXA) T-Score less than -2.
  • Scans done will include total body, dual hips and knees.

Outcomes

Primary Outcomes

Surface electromyography of 6 different muscle groups

Time Frame: 6 months

The EMG activity from 6 major leg muscles will be measured during locomotion

Six minute-walk and 10-meter walk distance Tests

Time Frame: 6 months

Walking distance and speed will also be determined

Secondary Outcomes

  • Oxygen uptake using Portable Indirect Calorimetry(6 months)
  • Systolic and Diastolic Blood Pressure(6 months)
  • Body composition assessment of fat mass and fat-free mass using dual energy x-ray absorptiometry (DXA)(6 months)

Study Sites (1)

Loading locations...

Similar Trials